96 results
Page 3 of 5
8-K
k71dw06d
7 Apr 20
Departure of Directors or Certain Officers
8:01am
8-K
EX-10.1
6md5 617xt46zuy
12 Mar 20
Sientra Announces $60 Million Convertible Notes Investment from
4:40pm
8-K
EX-99.1
wmsmo2
13 Jan 20
Sientra Announces Preliminary Unaudited 4Q19 Net Sales
5:25pm
8-K
EX-10.1
wr3s4q
7 Nov 19
Entry into a Material Definitive Agreement
4:38pm
8-K
EX-10.2
d4p77l27285yp1nm0dh
7 Nov 19
Entry into a Material Definitive Agreement
4:38pm
8-K/A
EX-99.1
9soihfz63uiblsv
9 Aug 19
Sientra Reports Second Quarter 2019 Financial Results
4:25pm
8-K
EX-99.1
e2qnp3o0mo9fvpls
8 Aug 19
Sientra Reports Second Quarter 2019 Financial Results
4:21pm
8-K
EX-1.1
nlzr awnlct
5 Jun 19
Sientra Commences Public Offering of Common Stock
4:10pm
424B5
dt24w3zatm0le8bftob
5 Jun 19
Prospectus supplement for primary offering
4:03pm
424B5
mjx fv9jh
3 Jun 19
Prospectus supplement for primary offering
4:01pm
8-K
EX-99.1
e4v yg1is
21 Mar 19
Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter
4:40pm
8-K
EX-99.1
69j03dm
12 Mar 19
Sientra Reports Fourth Quarter and Full Year 2018 Financial Results
4:31pm